The animals' B cells then underwent affinity maturation, producing potent human antibodies in a short amount of time. As a proof of concept, Farzan, Yin, and colleagues introduced the genomes for HIV ...
Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...
Early clinical data and additional preclinical data of HB2198 will be presented at the American College of Rheumatology (ACR) Convergence 2026REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- ...
B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...
B cells can control responses of myeloid cells through the release of particular cytokines (small proteins that control the growth and activity of cells in the immune system), challenging the ...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...
B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.
B-cell lymphoma may cause abdominal swelling, chest pressure, and bone weakening as lymphoma cells affect different organs. Treatments like chemotherapy and immunotherapy for B-cell lymphoma may ...
B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results